When the effort required by rodents to obtain palatable food was assessed, exendin-4 was found to decrease operant responding on both fixed and progressive ratio schedules, further supporting a reduction in the motivational drive for palatable foods ( However, it is worth noting that most preclinical studies do not incorporate a dose titration phase, a gradual increase to the therapeutic maintenance dose, which is standard in clinical settings
The latest trial results come amid a boom of drugs touted as the cure-all for weight loss
Link JC, Wiese CB, Chen X, et al
When to contact your GP or diabetes team : Persistent vomiting preventing fluid intake Severe abdominal pain, especially if radiating to the back (possible pancreatitis) Right upper abdominal pain, fever or jaundice (possible gallbladder problems) Signs of dehydration (dark urine, dizziness, reduced urination) Unexplained hypoglycaemia if on combination therapy New or worsening visual symptoms (especially if you have diabetic retinopathy) Allergic reactions (rash, swelling, breathing difficulties) Most patients tolerate GLP-1 medications well once past the initial adjustment period